PEDIATRICS Vol. 115 No. 5 May 2005, pp. 1220-1232 (doi:10.1542/10.1542/peds.2004-2514)
Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States
* Divisions of Viral Hepatitis
Health Care Quality Promotion
|| Bacterial and Mycotic Diseases, National Center for Infectious Diseases
Epidemiology and Surveillance Division, National Immunization Program, US Centers for Disease Control and Prevention, Atlanta, Georgia
Context. The US Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years.
Objective. To evaluate and compare the projected health and economic impact of MCV-4 vaccination of US adolescents, toddlers, and infants.
Design. Cost-effectiveness analysis from a societal perspective based on data from Active Bacterial Core Surveillance (ABCs) and other published and unpublished sources. Sensitivity analyses in which key input measures were varied over plausible ranges were performed.
Setting and Patients. A hypothetical 2003 US population cohort of children 11 years of age and a 2003 US birth cohort.
Interventions. Hypothetical routine vaccination of adolescents (1 dose at 11 years of age), toddlers (1 dose at 1 year of age), and infants (3 doses at 2, 4, and 6 months of age). Each vaccination scenario was compared with a "no-vaccination" scenario.
Main Outcome Measures. Meningococcal cases and deaths prevented, cost per case prevented, cost per life-year saved, and cost per quality-adjusted life-year saved.
Results. Routine MCV-4 vaccination of US adolescents (11 years of age) would prevent 270 meningococcal cases and 36 deaths in the vaccinated cohort over 22 years, a decrease of 46% in the expected burden of disease. Before program costs are counted, adolescent vaccination would reduce direct disease costs by $18 million and decrease productivity losses by $50 million. At a cost per vaccination (average public-private price per dose plus administration fees) of $82.50, adolescent vaccination would cost society $633000 per meningococcal case prevented and $121000 per life-year saved. Key variables influencing results were disease incidence, case-fatality ratio, and cost per vaccination. The cost-effectiveness of toddler vaccination is essentially equivalent to adolescent vaccination, whereas infant vaccination would be much less cost-effective.
Conclusions. Routine MCV-4 vaccination of US children would reduce the burden of disease in vaccinated cohorts but at a relatively high net societal cost. The projected cost-effectiveness of adolescent vaccination approaches that of recently adopted childhood vaccines under conditions of above-average meningococcal disease incidence or at a lower cost per vaccination.
Key Words: meningococcal vaccines • cost-benefit analysis • United States
Abbreviations: Hib, Haemophilus influenzae type b • MCV-4, quadrivalent meningococcal conjugate polysaccharide A/C/Y/W-135 vaccine • ABCs, Active Bacterial Core Surveillance • HUI, health-utility index • QALY, quality-adjusted life-year • MMR, measles-mumps-rubella • NPV, net present value • BC, benefit-cost • CFR, case-fatality ratio
Accepted Feb 7, 2005.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  Report From the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years With Quadrivalent Meningococcal Conjugate Vaccine (MCV4) JAMA, June 25, 2008; 299(24): 2848 - 2849. [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Ortega-Sanchez, G. M. Lee, R. J. Jacobs, L. A. Prosser, N.-A. Molinari, X. Zhang, W. B. Baine, M. M. McCauley, T. Miller, and for the Working Group on Leading Economic Issues f Projected Cost-effectiveness of New Vaccines for Adolescents in the United States Pediatrics, January 1, 2008; 121(Supplement_1): S63 - S78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Widdowson, M. I. Meltzer, X. Zhang, J. S. Bresee, U. D. Parashar, and R. I. Glass Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States Pediatrics, April 1, 2007; 119(4): 684 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Rein, K. A. Hicks, K. E. Wirth, K. Billah, L. Finelli, A. E. Fiore, T. J. Hoerger, B. P. Bell, and G. L. Armstrong Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States Pediatrics, January 1, 2007; 119(1): e12 - e21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gardner Prevention of Meningococcal Disease N. Engl. J. Med., October 5, 2006; 355(14): 1466 - 1473. [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Harrison Prospects for Vaccine Prevention of Meningococcal Infection Clin. Microbiol. Rev., January 1, 2006; 19(1): 142 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Davis Varicella Vaccine, Cost-effectiveness Analyses, and Vaccination Policy JAMA, August 17, 2005; 294(7): 845 - 846. [Full Text] [PDF]
|
|
|
|
|
|
Committee on Infectious Diseases Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients Pediatrics, August 1, 2005; 116(2): 496 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Cost-Effectiveness of Conjugate Meningococcal Vaccine Journal Watch Infectious Diseases, May 20, 2005; 2005(520): 10 - 10. [Full Text]
|
|
